Huajin securities issued a research report on April 30, saying that it maintained the buy-b rating of Yantai Dongcheng Biochemicals Co.Ltd(002675) (002675.sz, latest price: 20.65 yuan). The reasons for rating mainly include: 1) the overall performance is affected by the epidemic, and the recovery is accelerated in the second half of the year; 2) Profitability is affected by the epidemic and product structure, and is expected to return to normal in 2021; 3) High barrier and high-quality track for nuclide drugs, with nuclear pharmacy as the core and scarce target; 4) Reach a number of cooperation and strengthen the leading position of nuclear drugs; 5) The R & D pipeline of nuclide drugs is constantly enriched, and the landing time of new drugs can be expected. Risk tip: the R & D speed is lower than expected; The construction speed of nuclear pharmacy did not meet expectations; Risk of API trade war; Goodwill impairment risk.
AI comments: Yantai Dongcheng Biochemicals Co.Ltd(002675) four research reports of securities companies have been paid attention to in the past month, three have been bought, and one is strongly recommended. The average target price is 25 yuan, 4.35 yuan higher than the latest price of 20.65 yuan, and the average target price has increased by 21.07%.
(Daily Economic News)
